Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Bevacizumab for Resected Pancreatic Cancer
NCT00410774Phase 2Terminated
- Sponsor
- University of California, San Francisco
- Start
- Jul 2006
- Primary completion
- Oct 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in pancreatic cancer (PC), sponsored by University of California, San Francisco. Started Jul 2006; status: terminated.
02
Drugs
bevacizumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00410774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410774.